Dose-Escalation Study of Cevostamab in Patients with Relapsed or Refractory Multiple Myeloma

The primary objective of this study is to evaluate the safety and tolerability of **Cevostamab** in participants with relapsed or refractory **Multiple Myeloma (MM)**. This is clinically relevant as it aims to determine the appropriate dosage levels that can be safely administered to patients, which is crucial for the development of effective treatment regimens for this condition. The study does not specify any secondary objectives.

The clinical trial involves a total of **185 participants** diagnosed with **Multiple Myeloma (MM)**. The study population includes both male and female subjects, encompassing an age range that includes adults and older adults. Participants were selected to ensure a representative sample of the general population affected by this condition. The trial includes individuals from a vulnerable population, indicating a careful consideration of ethical standards in participant selection. Lifestyle factors such as diet, physical activity, and habits were not specified by the sponsor. The trial does not provide specific inclusion or exclusion criteria, focusing instead on a broad demographic to assess the treatment's efficacy and safety across a diverse group of individuals.

The clinical trial is a **Phase 1** study designed to evaluate the safety and efficacy of Cevostamab in participants with **Multiple Myeloma**. The trial follows a **randomized, double-blind, controlled** design to ensure unbiased results. The estimated duration of the trial spans from October 30, 2020, to June 1, 2026, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following enrollment, participants will attend regular follow-up visits, which are structured to monitor their response to the treatment and to identify any adverse effects. These visits are integral to maintaining participant safety and the integrity of the trial data. The study will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial is determined by the study protocol, which outlines the specific duration of treatment and follow-up periods. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with study procedures, or withdraw consent. Such conditions are clearly defined to protect participant welfare and ensure the validity of the trial results.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided dataset. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, which typically focuses on assessing safety, tolerability, and pharmacokinetics, but may also include preliminary efficacy assessments. The trial is scheduled to commence recruitment on October 30, 2020, with an estimated completion date of June 1, 2026. Although specific efficacy endpoints are not detailed, Phase 1 trials often utilize a range of parameters such as biomarker levels, symptom improvement scores, or other relevant clinical measures to evaluate efficacy. These parameters are typically measured at various timepoints throughout the trial to monitor changes and assess the impact of the investigational product. The data collected will be analyzed using appropriate statistical methods to determine the efficacy of the treatment under investigation. The trial will adhere to rigorous standards to ensure the reliability and validity of the efficacy assessments.